FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma

Season 7 Episode 47  ·  Nov 14, 2022, 07:50 PM

Headliner
Share
Subscribe

Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.

Share
Subscribe
Next
Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air